SLC5A2 and cerebrovascular disorder: SGLT2 inhibitors, as a new type of hypoglycemic agent, not only have a good effect on blood glucose control but also have significant benefits on cardiovascular disease, cerebrovascular disease, body weight, blood pressure, blood lipid, kidney function, and other indicators [18, 19].